Chronic Kidney Disease Augments Gout Risks

By Jack Cush, MD | 09 April 2019

A population based cohort analysis shows that patients with incident gout and chronic kidney disease (CKD) have far worse outcomes than those without CKD.

A retrospective population-based cohort study of incident gout between 2006-2009 identified those with CKD; defined as a pre-existing diagnosis of chronic kidney disease, chronic renal failure, kidney transplantation, or dialysis at index date.

Among 12,940 incident adult gout patients, 64% with CKD and 36% without CKD, were followed for 55,206 person-years.

Overall, gout patients with CKD (vs those without CKD) had:

Significantly more healthcare utilization; Hospital admissions were at least 3 times higher for Gout+CKD adults < 55 (mean = 0.51 vs 0.13) and approximately 1.5 times higher for adults 55+ (mean = 0.46 vs 0.29) without CKD.
All-cause mortality was higher among those with CKD compared to those without CKD for both age groups (HR< 55 years = 1.65; 95% CI 1.01-2.71; HR55+ years = 1.50; 95% CI 1.37-1.65).

Gout plus CKD constitutes a high risk population that merits focused efforts to better control their gout and optimize comorbidity management.

Disclosures:

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may Login/Register to comment.

More Like This

Coexistent Gout Increases Risk in Rheumatoid Arthritis

By Jack Cush, MD | 16 May 2019

It his often said that gout and rheumatoid arthritis (RA) cannot coexist and where confusion exists, a good history and testing for serum urate (SUA) and rheumatoid factor (RF) can usually clarify the dominant disorders. A recent study shows that hyperuricemia and gout are uncommon in RA, but when present shows an increased risk of comorbidities and cardiovascular (CV) mortality.

[...]

Less Structural Damage with T2T in Gout

By Jack Cush, MD | 15 May 2019

A two‐year randomized clinical trial has demonstrated that allopurinol dose escalation to a target serum urate (SU) results in less bone erosion, structural damage and urate crystal deposition in patients with gout.

[...]

Ideal Outcomes are Seldom Achieved in Gout

By Jack Cush, MD | 02 May 2019

Studies from a cohort of gout patients in Mexico shows that long-term goals of a target serum urate (sUA) < 6 mg/dL and remission are rare, especially for those with severe gout.

[...]

Omega-3 Rich Fish Lowers Gout Flares

By Jack Cush, MD | 01 May 2019

Boston researchers have shown that consumption of fish rich in omega‐3 polyunsaturated fatty acids (n‐3 PUFA) leads to a lower risk of recurrent gout flares.

[...]

Ironwood Retreats from the US Gout Market

By Jack Cush, MD | 18 Mar 2019

Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019. In addition the Duzallo and Zurampic Patient Savings Program were also discontinued on December 31, 2018.

The company stated that this was a financial decision unrelated to the efficacy or safety of lesinurad.

You are here